HUTCHMED (China) Limited To Present Positive Phase III NSCLC Data at ESMO

HUTCHMED said two positive Phase III studies of savolitinib plus osimertinib in EGFR-mutated NSCLC will be presented at ESMO 2026, including SAFFRON in the Presidential Symposium and SANOVO in a Proffered Paper session.Material DetailsContext by AI AnalystThis builds on August high-level readouts…